Cadenza Bio, Inc.

Cadenza Bio, Inc. is a preclinical biotechnology company founded in 2022 that focuses on developing novel, non-steroidal, small-molecule drugs for oral administration. The company’s primary research centers on highly selective compounds targeting Estrogen Receptor β (ERβ), which are designed to address demyelinating and inflammatory diseases. By utilizing an exclusive license to technology developed through academic collaborations at the University of Illinois Urbana-Champaign and the University of California, Riverside, Cadenza Bio has demonstrated in preclinical animal models that its lead compounds can reduce inflammation, drive remyelination, and promote functional recovery. These therapies utilize a unique dual-action mechanism aimed at both neuroprotection and immunomodulation.

The company's work is particularly significant for patients suffering from conditions such as multiple sclerosis (MS) and endometriosis, where there are few existing options to repair myelin or reverse functional damage. Recent research published in Scientific Reports highlighted the efficacy of lead candidates K102 and K110 in mouse models of MS, demonstrating that these molecules possess the necessary pharmacokinetics for central nervous system exposure and oral dosing. Based in Oklahoma City, Cadenza Bio is actively working toward advancing these candidates into Phase 1 clinical trials to move beyond symptomatic treatment toward halting disease progression and restoring quality of life.